BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.